Revenue (Tables)

12 Months Ended

Dec. 31, 2023

Revenue [Abstract]

Revenue Recognized from Collaboration Agreements

Revenue from sale of therapies (in thousands)	2023		2022		2021
Product revenue	$	238,735	$	130,013	$	—
Pre-product revenue		—		10,674		4,078
Total revenue from sale of therapies		238,735		140,687		4,078
Collaboration revenue
GSK		—		—		8,385
Eli Lilly		—		9,205		—
Genentech		10,693		24,469		24,021
Total collaboration revenue		10,693		33,674		32,406
Total revenue	$	249,428	$	174,361	$	36,484

Revenue by Country/Region Based on Location of Customer

Net product revenue from the sale of KIMMTRAK, and net pre-product revenue are presented by country / region based on the location of the end customer below (in thousands).

	2023		2022		2021
United States	$	169,791	$	96,893	$	—
Europe		67,628		42,745		4,078
International		1,316		1,049		—
Total revenue from sale of therapies	$	238,735	$	140,687	$	4,078

Accounts Receivable, Net from Contracts with Customers

Accounts receivable, net as of December 31, 2023 and 2022 were as follows (in thousands):

	2023			2022
Beginning balance	$	33,584		$	7,334
Additions		307,255			206,442
Payments received		(288,211	)		(180,192	)
Provision		(535	)		—
Ending balance	$	52,093		$	33,584

Current and Non-current Accruals for Rebates and Chargebacks

Current and non-current accruals for rebates, chargebacks and returns as of December 31, 2023 and 2022 were as follows (in thousands):

	Rebates			Chargebacks			Returns			Total
As of January 1, 2022	$	3,391		$	—		$	—		$	3,391
Provisions related to sales in the period		24,141			16,597			969			41,707
Credits and payments made		(1,115	)		(12,944	)		(121	)		(14,180	)
As of December 31, 2022	$	26,417		$	3,653		$	848		$	30,918
Provisions related to sales in the period		59,160			25,467			1,937			86,564
Adjustments related to prior period sales		(1,861	)		(734	)		(237	)		(2,832	)
Credits and payments made		(19,759	)		(26,355	)		(1,810	)		(47,924	)
As of December 31, 2023	$	63,957		$	2,031		$	738		$	66,726